Prostate-Specific Antigen: Function, Testing, and Results

A blood test may measure it to:

• examine prostate-related symptoms;
• assist prostate-cancer screening;
• monitor diagnosed prostate cancer;
• evaluate response to treatment;
• check for possible recurrence after treatment.

PSA is a biological marker, not a diagnosis. A high or rising result requires careful interpretation.

The abbreviated form PSA is much more common in everyday healthcare communication.

Common expressions include:

• prostate-specific antigen level;
• PSA blood test;
• elevated PSA;
• total PSA;
• free PSA;
• rising PSA.

Examples:

• The laboratory measured his prostate-specific antigen.
• The clinician discussed the elevated PSA result.
• PSA levels were monitored after treatment.

After ejaculation, semen initially forms a gel-like material. PSA helps break down proteins in this material so that the semen becomes more liquid.

This process may:

• support sperm movement;
• help distribute sperm within semen;
• contribute to the normal consistency of ejaculate.

The protein itself does not create sexual pleasure or cause ejaculation. It is one component of the reproductive fluid released during ejaculation.

There is no single result that perfectly separates prostate cancer from noncancerous conditions. Clinicians may consider:

• the current PSA measurement;
• changes across repeated tests;
• the person’s age;
• prostate size;
• symptoms and examination findings;
• medications;
• family and medical history;
• imaging or additional test results.

An unexpectedly high result may be repeated before further testing is recommended.

Possible causes include:

• benign prostatic hyperplasia, or prostate enlargement;
• prostatitis or inflammation;
• prostate or urinary infection;
• recent ejaculation;
• recent prostate procedures;
• increasing age;
• urinary retention;
• physical activity that places pressure on the prostate.

Some medicines used for prostate enlargement may lower PSA measurements. A healthcare professional should therefore know about relevant medications, infections, procedures, and recent activities.

It may help detect some cancers earlier. However, it may also lead to:

• false-positive results;
• anxiety;
• additional imaging or biopsy;
• detection of slow-growing cancer that might never cause illness;
• treatment-related urinary or sexual complications.

For this reason, screening decisions should consider individual risk, age, health, personal preferences, and the possible consequences of further testing. Current guidance emphasizes informed discussion rather than treating one PSA test as automatically appropriate for everyone.

A PSA result alone cannot diagnose prostate cancer. Diagnosis may require imaging, examination, biopsy, or other tests.

Expected patterns depend on the treatment:

• after surgical removal of the prostate, PSA usually becomes extremely low;
• after radiation therapy, PSA may decline gradually because prostate tissue remains;
• during medication or hormone treatment, changes may help indicate how the cancer is responding.

Clinicians usually examine the pattern over time rather than relying on one isolated result.

The paraurethral glands, or Skene’s glands, in typical vulvar anatomy may produce PSA-like prostatic secretions. These tissues are therefore sometimes described as the female prostate.

This does not mean that routine blood PSA screening has the same purpose in people without a typical prostate.

A low PSA guarantees the absence of cancer.
Some cancers occur without a strongly elevated result.

PSA is a cancer treatment.
It is a protein used as a measurable marker.

One PSA result provides a complete diagnosis.
Trends and other clinical findings are often necessary.

Prostate-specific means it exists nowhere else.
Related paraurethral tissues may also produce it.

1. Prostate-specific antigen is produced mainly by prostate cells.
2. PSA helps semen become more liquid after ejaculation.
3. A blood test can measure prostate-specific antigen.
4. An elevated PSA does not automatically indicate cancer.
5. Prostate inflammation may temporarily increase the PSA level.
6. The clinician compared several PSA results over time.
7. PSA may be monitored after prostate-cancer treatment.
8. Paraurethral glandular tissue may also produce PSA.

The prostate conditions investigated through PSA testing—and treatments for those conditions—may affect erections, ejaculation, orgasm, fertility, urinary control, and sexual confidence. These effects come from the condition or treatment rather than from PSA itself.

Understanding prostate-specific antigen supports clearer communication about semen, ejaculation, prostate health, cancer testing, and the possible sexual effects of medical care.